Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for treating breast cancer

A breast cancer, hormone therapy technology, applied in chemical instruments and methods, pharmaceutical formulations, antibody medical ingredients, etc., can solve the problems of fewer treatment options for patients and a large risk of death

Inactive Publication Date: 2013-01-23
LES LAB SERVIER +2
View PDF17 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In these cases, patients may have fewer treatment options with an associated greater risk of death

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for treating breast cancer
  • Methods for treating breast cancer
  • Methods for treating breast cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0287] Example 1 Expression of gastrin gene in metastatic breast cancer cell lines

[0288] This example describes the expression of the gastrin (GAST) gene in metastatic breast cancer cell lines.

[0289] A. Method

[0290] GAST mRNA expression was quantified from RNA preparations of MCF-7, MDA-MB-231 and T47D cell lines using quantitative RT-PCR. Data are presented in comparison to the mRNA expression levels present in the SW480 cell line, a primary colorectal cancer cell line expressing high levels of gastrin mRNA.

[0291] MCF-7 cells are a metastatic human breast cancer cell line. They were originally derived from the pleural effusion of patients diagnosed with breast cancer. MDA-MB-231 cells are metastatic human breast cancer cell lines. They were originally derived from the pleural effusion of patients diagnosed with breast cancer. T47D cells are a metastatic human breast cancer cell line. They were originally derived from the pleural effusion of a patient diagnos...

Embodiment 2

[0294] Example 2 Expression of gastrin gene in primary and metastatic breast tumors surgically removed from patients

[0295] This example describes the expression of the gastrin gene (GAST) in primary and metastatic breast cancer surgically removed from patients.

[0296] A. Method

[0297] Primary and metastatic breast cancers were surgically removed from different patients in accordance with applicable ethical guidelines. RNA was prepared from cancer samples and gastrin mRNA was measured by quantitative RT-PCR. Gastrin mRNA expression in clinical samples was normalized to expression levels in MCF-7 cells.

[0298] B. Results

[0299] A total of 105 primary breast cancers and 25 metastatic breast cancers were tested for gastrin gene expression. Progastrin mRNA in 27 tested primary tumors ( figure 2 ) neutralized in 7 metastatic tumors tested ( image 3 ) can be detected. Thus, gastrin genes are expressed in subtypes of primary and metastatic breast cancers, and expre...

Embodiment 3

[0300] Example 3 Plasma progastrin concentration in breast cancer patients

[0301] This example describes the quantification of plasma levels of progastrin in patients with primary and metastatic breast cancer.

[0302] A. Method

[0303] Plasma progastrin concentrations were measured in healthy individuals as controls, and in 42 patients with metastatic breast cancer who had surgically removed the primary tumor and in 3 patients with primary breast cancer. A total of 104 healthy control samples were obtained from blood banks.

[0304] Plasma or serum progastrin level quantification was performed using a progastrin-specific sandwich ELISA technique similar to one previously described below.

[0305] Wells of a Nunc MaxiSORP 96-well plate were coated with a primary antibody specific for progastrin as follows. Anti-progastrin polyclonal antibodies specific for the carboxy-terminal region of progastrin were diluted to a concentration of 3 μg / ml in a solution of 50 mM, pH 9.6 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure is directed to methods of treating and preventing breast cancer or recurrence of breast cancer with compositions comprising anti-progastrin antibodies.

Description

[0001] 1. Cross-reference of related applications [0002] This application claims the benefit of Provisional Application No. 61 / 293,612, filed January 8, 2010, under 35 U.S.C. § 119(e), the contents of which are hereby incorporated by reference in their entirety. [0003] 2. Reference to sequence listings, tables or computer programs [0004] The Sequence Listing is submitted at the same time. 3. Field of Invention [0005] In particular, the present disclosure relates to methods of treating and preventing breast cancer and its recurrence by administering a composition comprising an antibody specific for progastrin. 4. Background technology [0006] Despite decades of basic and clinical research, breast cancer remains one of the most lethal non-communicable diseases that primarily affects women, although men are also diagnosed with the disease. According to the GLOBOCAN project of the World Health Organization's International Agency for Research on Cancer, the estimated i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/26A61K39/395A61P35/00
CPCG01N2333/595A61K39/39558C07K2317/34G01N33/57438C07K16/26G01N2800/52C07K2317/73C07K16/303A61P35/00A61P35/04A61K39/395
Inventor J-F·弗洛克L·扈胡F·卡耶D·朱伯特F·霍兰德
Owner LES LAB SERVIER
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com